Page 98 - Read Online

Stuivenberg et al. Microbiome Res Rep 2025;4:11 https://dx.doi.org/10.20517/mrr.2024.22 Page 15 of 18

8. Hemarajata P, Versalovic J. Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and
neuromodulation. Therap Adv Gastroenterol 2013;6:39-51. DOI PubMed PMC
9. Nguyen TTU, Kim HW, Kim W. Effects of probiotics, prebiotics, and synbiotics on uremic toxins, inflammation, and oxidative stress
in hemodialysis patients: a systematic review and meta-analysis of randomized controlled trials. J Clin Med 2021;10:4456. DOI
PubMed PMC
10. Stuivenberg GA, Chmiel JA, Akouris PP, Burton JP, Reid G. Probiotic bifidobacteria mitigate the deleterious effects of para-cresol
in a drosophila melanogaster toxicity model. mSphere 2022;7:e0044622. DOI PubMed PMC
11. Din AU, Hassan A, Zhu Y, Yin T, Gregersen H, Wang G. Amelioration of TMAO through probiotics and its potential role in
atherosclerosis. Appl Microbiol Biotechnol 2019;103:9217-28. DOI PubMed
12. Spence JD, Solo K. Resistant atherosclerosis: the need for monitoring of plaque burden. Stroke 2017;48:1624-9. DOI PubMed
13. Baber U, Mehran R, Sartori S, et al. Prevalence, impact, and predictive value of detecting subclinical coronary and carotid
atherosclerosis in asymptomatic adults: the BioImage study. J Am Coll Cardiol 2015;65:1065-74. DOI PubMed
14. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature
2011;472:57-63. DOI PubMed PMC
15. Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes
atherosclerosis. Nat Med 2013;19:576-85. DOI PubMed PMC
16. Zhen J, Zhou Z, He M, et al. The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases. Front Endocrinol
2023;14:1085041. DOI PubMed PMC
17. Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med
2013;368:1575-84. DOI PubMed PMC
18. Zhu W, Gregory JC, Org E, et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell
2016;165:111-24. DOI PubMed PMC
19. Tang WHW, Wang Z, Kennedy DJ, et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both
development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res 2015;116:448-55. DOI PubMed PMC
20. Pignanelli M, Bogiatzi C, Gloor G, et al. Moderate renal impairment and toxic metabolites produced by the intestinal microbiome:
dietary implications. J Ren Nutr 2019;29:55-64. DOI
21. Olechnowicz-Tietz S, Gluba A, Paradowska A, Banach M, Rysz J. The risk of atherosclerosis in patients with chronic kidney disease.
Int Urol Nephrol 2013;45:1605-12. DOI PubMed PMC
22. Wang Z, Bergeron N, Levison BS, et al. Impact of chronic dietary red meat, white meat, or non-meat protein on trimethylamine N-
oxide metabolism and renal excretion in healthy men and women. Eur Heart J 2019;40:583-94. DOI PubMed PMC
23. Pathak P, Helsley RN, Brown AL, et al. Small molecule inhibition of gut microbial choline trimethylamine lyase activity alters host
cholesterol and bile acid metabolism. Am J Physiol Heart Circ Physiol 2020;318:H1474-86. DOI PubMed PMC
24. Liu H, Chen X, Hu X, et al. Alterations in the gut microbiome and metabolism with coronary artery disease severity. Microbiome
2019;7:68. DOI PubMed PMC
25. Verhaar BJH, Prodan A, Nieuwdorp M, Muller M. Gut microbiota in hypertension and atherosclerosis: a review. Nutrients
2020;12:2982. DOI PubMed PMC
26. Shen X, Li L, Sun Z, et al. Gut microbiota and atherosclerosis-focusing on the plaque stability. Front Cardiovasc Med
2021;8:668532. DOI PubMed PMC
27. Plaza-Diaz J, Ruiz-Ojeda FJ, Gil-Campos M, Gil A. Mechanisms of action of probiotics. Adv Nutr 2019;10:S49-66. DOI PubMed
PMC
28. Melamed ML, Plantinga L, Shafi T, et al. Retained organic solutes, patient characteristics and all-cause and cardiovascular mortality
in hemodialysis: results from the retained organic solutes and clinical outcomes (ROSCO) investigators. BMC Nephrol 2013;14:134.
DOI PubMed PMC
29. Cantero MA, Guedes MRA, Fernandes R, Lollo PCB. Trimethylamine N-oxide reduction is related to probiotic strain specificity: a
systematic review. Nutr Res 2022;104:29-35. DOI PubMed
30. Tang J, Qin M, Tang L, et al. Enterobacter aerogenes ZDY01 inhibits choline-induced atherosclerosis through CDCA-FXR-FGF15
axis. Food Funct 2021;12:9932-46. DOI PubMed
31. Gryp T, Vanholder R, Vaneechoutte M, Glorieux G. p-Cresyl sulfate. Toxins 2017;9:52. DOI PubMed PMC
32. Kwiatkowska I, Hermanowicz JM, Mysliwiec M, Pawlak D. Oxidative storm induced by tryptophan metabolites: missing link
between atherosclerosis and chronic kidney disease. Oxid Med Cell Longev 2020;2020:6656033. DOI PubMed PMC
33. Ramezani A, Massy ZA, Meijers B, Evenepoel P, Vanholder R, Raj DS. Role of the gut microbiome in uremia: a potential
therapeutic target. Am J Kidney Dis 2016;67:483-98. DOI PubMed PMC
34. Meijers BK, Claes K, Bammens B, et al. p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol
2010;5:1182-9. DOI PubMed PMC
35. Nakano T, Katsuki S, Chen M, et al. Uremic toxin indoxyl sulfate promotes proinflammatory macrophage activation via the interplay
of OATP2B1 and Dll4-notch signaling. Circulation 2019;139:78-96. DOI PubMed PMC
36. Opdebeeck B, Maudsley S, Azmi A, et al. Indoxyl sulfate and p-cresyl sulfate promote vascular calcification and associate with
glucose intolerance. J Am Soc Nephrol 2019;30:751-66. DOI PubMed PMC
37. Dobre M, Meyer TW, Hostetter TH. Searching for uremic toxins. Clin J Am Soc Nephrol 2013;8:322-7. DOI PubMed PMC